First-line Treatment of Children with ALL and Management of Asparaginase-Associated Hypersensitivity – Insights from the US
Dr. Michael Burke is a Professor at the Medical College of Wisconsin, Department of
Pediatrics, Division of Hematology/Oncology/Bone Marrow Transplantation. He is the
Director of the Leukemia & Lymphoma Program at Children’s Hospital of Wisconsin
and has developed local and national clinical trials in acute leukemia with consortiums
such as the Children’s Oncology Group (COG) and Therapeutic Advances in Childhood
Leukemia & Lymphoma (TACL).
Dr Burke’s research interests have primarily focused on the development of early phase
clinical trials investigating novel agents and/or combination therapies for relapsed/
refractory leukemia. Specifically, Dr Burke has been investigating the role of epigenetic
modifying therapies in acute leukemias such as the histone deacetylase inhibitors and
DNA methyltransferase inhibitors.
Expert presentation (20 minutes)
First-line Treatment and Management of Hypersensitivity in Pediatric Patients with
ALL – The Children’s Oncology Group Experience
Live Q&A with Prof Michael J. Burke (10 minutes)